Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03529422 · OUTCOME

Disease-free Survival Rate

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN · Source last updated 2026-06-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
3 years

What was measured

Disease-free Survival Rate (DFS) defined as the percentage of participants who were disease-free and alive at 3 years, counting the time from day 1 of treatment to time of disease recurrence or death, was calculated based on the Kaplan-Meier method.

Analysis population: Participants started to study treatment and treatment responses were assessed.

Groups in this outcome

Open-label, Single-arm

Durvalumab in combination with intensity modulated radiotherapy (IMRT) treatments Durvalumab: Durvalumab 1500mg IV every 3 weeks for 6 cycles Intensity Modulated Radiotherapy Treatments: Total dose will be 60 Gray (Gy) at 2Gy per fractions for 30 fractions delivered Monday through Friday for 6 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Open-label, Single-arm16

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Open-label, Single-arm68.8Not reported46.091.5Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        46.0
        upper Limit
        91.5
        value
        68.8
denoms
  1. counts
    1. group Id
      OG000
      value
      16
    units
    Participants
description
Disease-free Survival Rate (DFS) defined as the percentage of participants who were disease-free and alive at 3 years, counting the time from day 1 of treatment to time of disease recurrence or death, was calculated based on the Kaplan-Meier method.
dispersion Type
95% Confidence Interval
groups
  1. description
    Durvalumab in combination with intensity modulated radiotherapy (IMRT) treatments Durvalumab: Durvalumab 1500mg IV every 3 weeks for 6 cycles Intensity Modulated Radiotherapy Treatments: Total dose will be 60 Gray (Gy) at 2Gy per fractions for 30 fractions delivered Monday through Friday for 6 weeks
    id
    OG000
    title
    Open-label, Single-arm
param Type
NUMBER
population Description
Participants started to study treatment and treatment responses were assessed.
reporting Status
POSTED
time Frame
3 years
title
Disease-free Survival Rate
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice